Dr. Han Myint Appointed as NextCure’s Chief Medical Officer
January 14, 2021 16:05 ET | Source: NextCure NextCure Beltsville, Maryland, UNITED STATES
BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer. Dr. Myint will oversee the clinical development of key products in NextCure’s product pipeline, including NC318, a first-in-class immunomedicine, targeting Siglec-15 (S15), and NC410, recombinant LAIR-2 fusion protein designed to block immune suppression mediated by the immune modulator LAIR-1. Prior to joining NextCure, Dr. Myint held senior roles at both Celgene (a Bristol Myers Squibb Company) and NexImmune Inc.
Pulmonary Fibrosis Foundation Announces Sponsorship by United Therapeutics
News provided by
Share this article
CHICAGO, Jan. 14, 2021 /PRNewswire/ The
Pulmonary Fibrosis Foundation (PFF), the nation s leading pulmonary fibrosis (PF) education and advocacy organization, has announced United Therapeutics sponsorship of the PFF Registry, a research resource that tracks clinical data, blood samples and patient-reported outcomes from individuals living with PF nationwide.
United Therapeutics has joined the Pulmonary Fibrosis Foundation (PFF) as a sponsor of the PFF Registry, a research resource that tracks clinical data, blood samples, and patient-reported outcomes from individuals living with pulmonary fibrosis nationwide.
United Therapeutics is a leading biotechnology company with a mission to develop treatments for rare diseases, including pulmonary hypertension (PH) and idiopathic pulmonary fibrosis (IPF). The sponsorship will help researchers working to address the unmet
Press release content from Accesswire. The AP news staff was not involved in its creation.
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
January 12, 2021 GMT
PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT).
(2)
PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT). With the acceptance of the NDS by Health Canada, review of the data can begin, an important step on the path to making tafasitamab available in Canada for use in combination with lenalidomide in eligible patients with relapsed or refractory DLBCL, said Josée Brisebois, Ph.D., Head of Medical Affairs, Incyte Biosciences Canada. We intend to work clo
Might COVID Enable Structural Reforms? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.